Recent results from a phase I/II study of intrathecal trastuzumab in HER-2 positive cancer with NM showed an OS of 8.3 months for patients with any HER-2 positive histology and 10.5 months in HER-2 positive breast cancer [54]. This evidence concerns the gene ERBB2 and breast carcinoma.